Compare KIDS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | ADCT |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.2M | 484.4M |
| IPO Year | 2016 | 2019 |
| Metric | KIDS | ADCT |
|---|---|---|
| Price | $16.92 | $3.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $24.67 | $7.75 |
| AVG Volume (30 Days) | 146.6K | ★ 647.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,049,000.00 | $81,357,000.00 |
| Revenue This Year | $14.07 | N/A |
| Revenue Next Year | $11.85 | $66.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.95 | 14.85 |
| 52 Week Low | $14.91 | $1.13 |
| 52 Week High | $23.70 | $4.98 |
| Indicator | KIDS | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 48.68 |
| Support Level | $16.74 | $3.65 |
| Resistance Level | $19.15 | $3.88 |
| Average True Range (ATR) | 0.71 | 0.21 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 94.66 | 63.08 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).